logo
logo

BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments

Feb 10, 2021•over 4 years ago

Amount Raised

$19 Million

Round Type

series a

San Carlos

Description

BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreessen Horowitz, with participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors. As part of the investment, Andreessen Horowitz General Partner, Vineeta Agarwala, MD, PhD joins BigHat’s Board of Directors.

Company Information

Company

Bighat Biosciences

Location

San Carlos, California, United States

About

ABOUT BIGHAT BIOSCIENCES Founded in 2019 and headquartered in San Carlos, CA, BigHat Biosciences is developing an AI-guided protein therapeutic design platform that integrates a high-speed antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by 8VC, Andreessen Horowitz, AME Cloud Ventures, and Innovation Endeavors. Find BigHat Biosciences online: https://www.bighatbio.com/

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech